Sponsors (5)
The bill trades increased international coordination and potential faster progress against Alzheimer’s (benefiting patients, researchers, and low‑income countries) for greater federal financial commitments, constrained U.S. leverage in multilateral governance, and risks of diverting attention or funds from domestic priorities.
People with Alzheimer’s and other dementias in the U.S. (and worldwide) could gain earlier, more accurate diagnoses and improved prevention and treatment options through increased international research coordination and shared data/resources.
U.S. researchers, hospitals, and universities will benefit from coordinated global research partnerships, shared data and resources, and capacity-building that can accelerate scientific progress.
Low- and middle-income countries and their populations may receive increased development cooperation and resources for dementia care and research, helping address the majority of future global cases and advancing global health equity.
U.S. taxpayers could face increased costs or contingent obligations if the government makes new international commitments or uses existing foreign assistance accounts to fund contributions without offsets.
Directing U.S. leadership and funds toward international collaborations risks diverting attention and resources away from domestic Alzheimer’s research, care, and services.
Partnerships with multilateral non‑governmental entities could raise public accountability and influence concerns over research agendas and governance, reducing transparency and public control.
Based on analysis of 4 sections of legislative text.
Authorizes U.S. participation and contributions to the Davos Alzheimer’s Collaborative, permits use of specified foreign assistance authorities, sets a U.S. funding cap (≤33% FY2026–FY2030), and requires reports to Congress.
Authorizes the United States to join and contribute to the Davos Alzheimer’s Collaborative (DAC) to support international prevention, diagnosis, and treatment of Alzheimer’s disease and other dementias, with a U.S. funding cap and required coordination among USAID, State, and HHS. It requires a presidential designee for DAC governance, allows use of specified foreign assistance authorities for contributions, and mandates an initial and annual report to key congressional committees on U.S. participation and planned contributions. The bill frames Alzheimer’s and dementia as a fast-growing global health and economic problem—especially in low- and middle-income countries—and sets U.S. policy to lead cooperative international efforts that develop diagnostics and treatments for diverse populations, promote development cooperation, and leverage U.S. investments through burden-sharing with multilateral partners.
Introduced June 3, 2025 by Ami Bera · Last progress June 3, 2025